@FierceBiotech: Turns out drugmakers don't tell the whole truth about FDA rejections. More | Follow @FierceBiotech
@JohnCFierce: This will be a biotech to watch: Unum hits the gas on next-gen CAR-T tech after banking $65M round. Story | Follow @JohnCFierce
@DamianFierce: Listen to two arguably well-informed people talk about the week in biopharma. FierceBiotech Radio | Follow @DamianFierce
> U.K. biopharma investor Neil Woodford has dumped his stake in Sanofi ($SNY) and redoubled his bets on emerging biotech companies around Europe. News
> GlaxoSmithKline ($GSK), in the process of consolidating much of its U.S. R&D division, offered a glimpse at a planned research hub in Pennsylvania. Story
> Alnylam's ($ALNY) RNAi treatment for autoimmune disorders successfully silenced its target by as much as 96% in a study on 12 healthy volunteers. The company plans to move the candidate into a trial on the rare paroxysmal nocturnal hemoglobinuria by the end of the year. More
Medical Device News
@FierceMedDev: Illumina teams up with Chinese genomics firm for noninvasive prenatal test development. FierceDiagnostics story | Follow @FierceMedDev
@VarunSaxena2: Boston Scientific touts improved spinal cord stimulator at neuromodulation conference. Article | Follow @VarunSaxena2
@EmilyWFierce: ICYMI yesterday: FDA slaps Insulet with warning letter over insulin pumps. Article | Follow @EmilyWFierce
> Boston Scientific touts improved spinal cord stimulator at neuromodulation conference. Story
> Philips cautions on cardio mortality after ResMed sleep apnea data, intros cardiac imaging tool. Article
Pharma News
@FiercePharma: AB Science struggles to break out as canine cancer drug flounders. FierceAnimalHealth story | Follow @FiercePharma
@EricPFierce: Mylan recalls more injected cancer drugs it made for #Pfizer at its Agila plants in India. ICYMI from FiercePharmaManufacturing | Follow @EricPFierce
@CarlyHFierce: ICYMI yesterday: Big Data study flags 'fairly compelling' link between stomach blockbusters and heart risks. Report | Follow @CarlyHFierce
> GSK deal keeps paying off for Novartis with more positive Arzerra data. Story
> Prisoners accuse Massachusetts of barring them from pricey hep C meds. Article